# Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

> **NCT05181605** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Instituto de investigación e innovación biomédica de Cádiz** · enrollment: 116 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** Folfirinox and Stereotactic Body Radiotherapy

## Key facts

- **NCT ID:** NCT05181605
- **Lead sponsor:** Instituto de investigación e innovación biomédica de Cádiz
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-15
- **Primary completion:** 2023-04-15
- **Final completion:** 2024-12-01
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181605, "Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05181605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*